Know Cancer

forgot password

The PreMiO Study: The Prevalence of Malnutrition in Oncology.

18 Years
Open (Enrolling)
Malnutrition, Pre-cachexia, Cancer

Thank you

Trial Information

The PreMiO Study: The Prevalence of Malnutrition in Oncology.

The acronym of the project "PreMiO" means "Prevalence of Malnutrition in Oncology".

The project arises from the observation that the negative consequences of cancer-related
malnutrition and cachexia are still largely underestimated in most oncology units , both in
Europe and the USA. Indeed, the prevention and treatment of the nutritional and metabolic
sequelae of cancer and its treatment, are not perceived as a priority by most oncologists.
This is quite surprising, considering the body of evidence demonstrating that the
deterioration of the nutritional status adversely affects treatment response, morbidity,
quality of life and survival of cancer patients. In other words, malnourished or cachectic
cancer patients lose chances to be adequately treated for their underlying disease.
Approximately one quarter of all deaths in western society are due to cancer. Half of all
patients with cancer lose body weight; one third lose more than 5% of their original body
weight and up to 20% of all cancer deaths are caused directly by cachexia. The greatest
prevalence of weight loss is seen among patients with solid tumours: gastric, pancreatic,
lung, colorectal, and head and neck. The overall prevalence of weight loss in cancer
patients may rise as high as 86% in the last 1-2 weeks of life.The pathogenesis of weight
loss, malnutrition and cachexia in cancer is multifactorial and represent the result of the
complex interplay between the tumor, host's metabolism, tumor-derived and host-derived
humoral factors, and the negative consequences of anticancer treatments on the patient's
ability to assume, absorb and metabolize nutrients.

Objectives The objective of the PreMiO project is to obtain data on the prevalence of
malnutrition in Italian cancer patients undergoing the first medical oncology visit. The
project is innovative since an oncologist, not a nutrition specialist, will perform the
nutritional evaluation of the patients.

The data obtained will contribute to increase the awareness of metabolic and nutritional
problems in oncology, favoring the inclusion of the initial assessment and
nutritional-metabolic monitoring in oncological protocols.

Patients and Methods "PreMIO" will be a prospective, multicentre observational study,
designed to assess the nutritional status in cancer patients presenting for the first visit
to an oncological center. Enrollment will be conducted at Italian ESMO-accredited centers
and in other medical oncological centers in Italy. Six-thousand patients have been
considered an adequate sample for a suitable estimation of the prevalence of malnutrition in
Italian cancer patients at first medical oncology visit. Patient recruitment will be ensured
through enrollment by 60 centers throughout the Italian national territory (North, Center,
South). The instruments used for patients' evaluation will be the Mini Nutritional
Assessment ® (MNA ®) and the criteria for the diagnosis of pre-cachexia elaborated by ESPEN.
Pre-cachexia is a clinical condition characterized , in the context of a chronic disease
(i.e. cancer), by unintentional weigh loss ≤ 5% during last 6 months, chronic systemic
inflammation and anorexia or anorexia-related symptoms. Although other nutritional tools are
available for nutritional status evaluation (Nutritional Risk Screening 2002, NRS 2002;
Malnutrition Universal Screening Tool, MUST), even in oncological setting (Subjective Global
Assessment, SGA; Patient-Generated Subjective Global Assessment, PG-SGA), we choose MNA®
for its diagnostic sensitivity and its rapidity of administration. The MNA ® consists of a
first screening part and of a second part as global assessment, which allows to obtain a
score reflecting the patient nutritional status. Moreover, this instrument was recently
considered the best screening method of nutrition status in patients with metastatic lung
cancer. The data generated in each participating center will be collected by the Coordinator
Centre (IDI-IRCCS). Patients will be stratified according to cancer type and localization,
disease stage, age, sex, general condition. It is expected that the prevalence of
malnutrition and pre- cachexia will vary widely, depending on tumor type, localization,
stage and previous surgical treatment. Multivariate analysis will allow to discriminate
among the factors contributing to the occurrence and prevalence of malnutrition in the study

Inclusion Criteria:

- patients at first medical oncology visit

- diagnosis of solid tumor

- age > 18 years

- no previous anticancer therapies (e.g. radiotherapy or chemotherapy)

- Life expectancy >3 months according with PaP score

- Informed consent

Exclusion Criteria:

- Oral feeding incapacity or intestinal obstruction

- Decompensated metabolic disorders

- Severe liver failure (total bilirubin >1.5 mg/dL (25μmol/L), and AST (SGOT)/ ALT
(SGPT) >2 x ULN or, in the case of metastatic liver, > 5 x ULN) or severe kidney
failure (creatinine > 2.0 mg/dL (177 μmol/L), creatinine clearance ClCr < 50ml/min).

- Acute Decompensated heart failure

- Active infection

- Primary brain tumors or metastatic brain tumors

- severe psychiatric disorders

- MMSE < 25/30 (in patient aged >70).

- Inadequate logistical support for the study participation.

Type of Study:


Study Design:

Observational Model: Ecologic or Community, Time Perspective: Prospective

Outcome Measure:


Outcome Description:

Malnutrition will be assessed by Mini Nutritional Assessment, biochemical analysis and diagnostic criteria of pre-cachexia.

Safety Issue:



Italy: National Bioethics Committee

Study ID:




Start Date:

June 2012

Completion Date:

December 2012

Related Keywords:

  • Malnutrition
  • Pre-cachexia
  • Cancer
  • Malnutrition
  • pre-cachexia
  • cancer
  • cachexia
  • MNA
  • weight loss
  • Cachexia
  • Malnutrition